Atrial Fibrillation Clinical Trial
Official title:
Internet-based Cognitive Behavior Therapy for Atrial Fibrillation
Verified date | August 2019 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim is to evaluate if internet- delivered CBT, based on behavioral activation and exposure principles, improves wellbeing and QoL in symptomatic AF patients.The study will include 30 patients with symptomatic AF despite optimal medical treatment in accordance with current guidelines.
Status | Completed |
Enrollment | 19 |
Est. completion date | August 30, 2018 |
Est. primary completion date | August 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: A) Paroxysmal AF = once per month that causes moderate to severe symptoms and leads to significant distress or interferes with daily life (i.e. EHRA class = IIb) [31]; B) Age 18-75 years; C) Able to read and write in Swedish. Exclusion Criteria: C) Heart failure with severe systolic dysfunction (ejection fraction = 35%); D) Significant valvular disease; E) Other severe medical illness; F) Severe depression or risk of suicide; G) Alcohol dependency. - |
Country | Name | City | State |
---|---|---|---|
Sweden | Department of Clinical Neuroscience, Karolinska Institutet | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in The Atrial Fibrillation Quality of Life (AFEQT) | The AFEQT is an atrial fibrillation-specific measure that taps into the QoL-domains: symptoms, daily activities, treatment concern, and treatment satisfaction. | From baseline to 12 weeks | |
Primary | Change in The Atrial Fibrillation Quality of Life (AFEQT) | The AFEQT is an atrial fibrillation-specific measure that taps into the QoL-domains: symptoms, daily activities, treatment concern, and treatment satisfaction. | From baseline to 9 months. | |
Secondary | WHODAS 2.0 (12-item version) • | Change in general quality of life | From baseline to 12 weeks. | |
Secondary | WHODAS 2.0 (12-item version) • | Change in general quality of life: | From baseline to 9 months. | |
Secondary | Symptom checklist (SCL) | Change in AF related symptoms: | From baseline to 12 weeks. | |
Secondary | Symptom checklist (SCL) | Change in AF related symptoms: | From baseline to 9 months. | |
Secondary | Atrial Fibrillation Severity Scale | Change in symptomatic burden | From baseline to 12 weeks. | |
Secondary | Atrial Fibrillation Severity Scale | Change in symptomatic burden | From baseline to 9 months. | |
Secondary | Cardiac Anxiety Questionnaire | Change in symptom preoccupation: | From baseline to 12 weeks. | |
Secondary | Cardiac Anxiety Questionnaire | Change in symptom preoccupation | From baseline to 9 months. | |
Secondary | GAD-7 | Change in anxiety | From baseline to 12 weeks. | |
Secondary | GAD-7 | Change in anxiety | From baseline to 9 months. | |
Secondary | PHQ-9 | Change in depression: | From baseline to 12 weeks. | |
Secondary | PHQ-9 | Change in depression | From baseline to 9 months. | |
Secondary | Perceived stress scale | Change in stress reactivity | From baseline to 12 weeks. | |
Secondary | Perceived stress scale | Change in stress reactivity | From baseline to 9 months. | |
Secondary | Change in healthcare consumption and work loss: TIC-P | The Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry assesses societal cost during the last month. These costs include the participant's health care consumption (direct medical costs), time spent in other health promoting activities (direct non-medical costs), and sick leave, unemployment, and reduced work capacity at work and in the domestic realm (indirect non-medical costs). | From baseline to 12 weeks. | |
Secondary | Change in healthcare consumption and work loss: TIC-P | The Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry assesses societal cost during the last month. These costs include the participant's health care consumption (direct medical costs), time spent in other health promoting activities (direct non-medical costs), and sick leave, unemployment, and reduced work capacity at work and in the domestic realm (indirect non-medical costs). | From baseline to 9 months. | |
Secondary | Change in symtomatic burden: Holter ECG. | The patient will undergo a 24 h ECG assessment in order to measure objectively symptomatic burden (number and duration of symptomatic AF episodes and symptomatic "non-AF episodes") | From baseline to 12 weeks. | |
Secondary | Change in symptomatic burden: Holter ECG. | The patient will undergo a 24 h ECG assessment in order to measure objectively symptomatic burden (number and duration of symptomatic AF episodes and symptomatic "non-AF episodes") | From baseline to 9 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |